Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481091 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00481091 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 60 participants.
The verdict
NCT00481091, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. The Extension Study portion will allow active subjects to continue to receive ABT-263 for up to 11 years after the last subject transitions with less frequent study evaluations.
Interventions
- DRUG ABT-263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-07-25 |
| Est. Completion | 2022-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00481091
The ClinicalTrials.gov registry entry for NCT00481091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABT-263 is the first listed.
NCT00481091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00481091 about?
NCT00481091 is a clinical study titled "A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia". The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose. The Phase 2a portion of the study will evaluate ABT-263 at the defined recommend...
What is the current status of trial NCT00481091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-07-25. Estimated completion is 2022-05-12.
What interventions are being tested in trial NCT00481091?
The interventions under investigation include: ABT-263 (DRUG).
Who is sponsoring clinical trial NCT00481091?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.